Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation - Seite 2

Idorsia’s portfolio

Product / compound	Mechanism of action	Therapeutic area	Status
QUVIVIQ (daridorexant)	Dual orexin receptor antagonist	Insomnia	Commercially available in the US Germany, Italy, Switzerland, Spain, the UK, and Canada; Approved in the EU; Phase 2 in pediatric insomnia – recruiting Partners: Mochida & Sosei in Japan, Simcere in China and Hong Kong
Aprocitentan	Dual endothelin receptor antagonist	Resistant hypertension	NDA under review in the US, MAA under review in the EU, other filings in preparation Partner: Unencumbered
Lucerastat	Glucosylceramide synthase inhibitor	Fabry disease	Phase 3 primary endpoint not met; open-label extension study ongoing Partner: Unencumbered
Selatogrel	P2Y12 inhibitor	Suspected acute myocardial infarction	Phase 3 recruiting Partner: Unencumbered
Cenerimod	S1P1 receptor modulator	Systemic lupus erythematosus	Phase 3 recruiting Partner: Unencumbered
ACT-1004-1239	ACKR3 / CXCR7 antagonist	Multiple sclerosis and other demyelinating diseases	Phase 2 in preparation Partner: Unencumbered
Sinbaglustat	GBA2/GCS inhibitor	Rare lysosomal storage disorders	Phase 1 complete Partner: Unencumbered
ACT-1014-6470	C5aR1 antagonist	Immune-mediated disorders	Phase 1 Partner: Unencumbered
ACT-777991	CXCR3 antagonist	Recent-onset Type 1 diabetes	Phase 1 Partner: Unencumbered
IDOR-1117-2520	Undisclosed	Immune-mediated disorders	Phase 1 Partner: Unencumbered
IDO-090	Synthetic glycan vaccine	Clostridium difficile infection	Phase 1 in preparation Partner: Unencumbered

Neurocrine Biosciences has a global license to develop and commercialize ACT-709478 (NBI-827104), Idorsia's novel T-type calcium channel blocker.